Intellectual Property India Publishes Patent Application for Non-Invasive In-Vitro Method Of Diagnosis

MUMBAI, India, Oct. 5 -- Intellectual Property India has published a patent application (202527127714 A) filed by Medicover Biotech Ltd. on December 16, 2025, for Non-Invasive In-Vitro Method Of Diagnosis.

Inventors include Koumbaris, George; Achilleos, Achilleas; Eliades, Alexia; Lemesios, Christos; Kypri, Elena; Ioannides, Marios; Patsalis, Philippos; Tsangaras, Kyriakos; and Loizides, Charalambos.

The application for the patent was published on October 02, 2026, under issue no. 40/2026.

Abstract: The invention relates to an in-vitro method of diagnosis, prognosis, treatment response control, response prediction, of a particular human disease comprising the steps of: (i) providing for a human sample, preferably a blood sample from a subject, more preferably a plasma sample, or a serum sample or a buffy coat sample; (ii) preparing a first nucleic acid sequencing library from the nucleic acids present in said sample; (iii) hybridizing one or more TAC oligonucleotides from a first TAC oligonucleotide pool (TAC oligonucleotide-1) to said first nucleic acid library thereby isolating a first subset of library nucleic acid molecules; (iv) sequencing said first subset of library nucleic acid molecules and comparing the sequences determined to a human reference sequence, thereby creating a first group of putatively informative sequence variants (PISV 1); (v) hybridizing one or more TAC oligonucleotides from a second smaller TAC oligonucleotide pool comprising TAC oligonucleotides (TAC oligonucleotide-2) which are specific for the nucleic acid molecules of said first group of putatively informative sequence variants, to said first library of nucleic acid molecules thereby isolating a second subset of library nucleic acid molecules; (vi) sequencing said second subset of library nucleic acid molecules and comparing the sequences determined to a human reference sequence, thereby creating a second group of putatively informative sequence variants (PISV2); (vii) analyzing the putatively informative sequence variants (PISV2) thereby diagnosing, prognosing, controlling the response to a drug, for a particular human disease state. Steps (i) to (iv) are also referred to together as step A. Steps (v) to (vii) are also referred to together as step B.

Disclaimer: Curated by HT Syndication.